Fast and Ultra-Fast mRNA-Engineered Anti-CA125/MUC16 CAR-T-Cells: An In Vitro Study

556 A phase I first-in-human trial of IL-12 genetically engineered myeloid cells in participants with relapsed, refractory solid tumors
Steven Highfill, Sabina Kaczanowska, Jessica Lake +4
Journal for ImmunoTherapy of Cancer4 Nov 2026Peer-reviewedCC BYImmunology OncologyDOAJ
203 Dual targeting of uPAR and MICA/B with multiplexed-engineered CAR T cells offers a unique therapeutic strategy in fibrotic disease
Hui-Yi Chu, Bahram Valamehr, Soheila Shirinbak +11
Journal for ImmunoTherapy of Cancer4 Nov 2026Peer-reviewedCC BYFull textOncologyDOAJ
In vivo engraftment of vascular structures in 3D-engineered artificial tissues vascularized by cord blood- or peripheral blood-derived endothelial colony-forming cells
Yoshiya Asano, Yoshiko Tamai, Hiroshi Shimoda
Scientific Reports30 Sep 2026Peer-reviewedCC BY 4.0Full textSurgery & anaesthesiaCrossref
400 Proinflammatory and immune checkpoint responses in bystander tumor cells in an in vitro breast cancer model
Javier Mora, Fiorella Calderón-Milán, Lucia Figueroa-Protti
Journal for ImmunoTherapy of Cancer4 Nov 2026Peer-reviewedCC BYFull textOncologyDOAJ
Lipid-based mRNA chimeric antigen receptor T cells for enhanced in vitro antitumor activity
Haixia Gao, Yuan Fang, Zhidan Tian +6
iScience1 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossrefEurope PMC

Cite

BibTeX

@article{anon2026fast,
  title = {{Fast and Ultra-Fast mRNA-Engineered Anti-CA125/MUC16 CAR-T-Cells: An In Vitro Study}},
  journal = {Biomedicines},
  year = {2026},
  month = sep,
  url = {https://europepmc.org/article/PMC/PMC13701628},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - Fast and Ultra-Fast mRNA-Engineered Anti-CA125/MUC16 CAR-T-Cells: An In Vitro Study
PY  - 2026
DA  - 2026/09/23
JO  - Biomedicines
UR  - https://europepmc.org/article/PMC/PMC13701628
SN  - 2227-9059
ER  -

Related

Cite